Pipeline

CytomX’s proprietary Probody™ Platform is enabling the development of a diversified pipeline of empowered antibodies, including Probodies, Probody-Drug Conjugates (PDCs), bispecifics, multispecifics and other formats, addressing previously undruggable targets in cancer, inflammation and other areas of significant unmet medical need.

Programs in the CytomX pipeline are directed against two principal areas: novel, promising pathways for which drug development has been significantly limited by broad tissue expression, and clinically and commercially validated targets. CytomX’s Probodies are fully recombinant, masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment.

Epidermal Growth Factor Receptor
CytomX’s program targeting the Epidermal Growth Factor Receptor (EGFR) is currently in preclinical development. EGFR remains an important target in a number of solid tumor indications in which there remain significant unmet medical needs but in which there are no approved antibody therapeutics such as in non-small cell lung cancer. CTX-023, CytomX’s “naked” EGFR probody, has shown a substantial improvement in the therapeutic index in preclinical models. In addition, the Company’s EGFR-PDC has demonstrated potent preclinical activity when selectively activated within the tumor microenvironment. Preclinical data were presented at AACR 2013.

Notch Pathway
CytomX is working on a novel, first-in-class Probody program targeting Jagged, a ligand in the Notch pathway. Research suggests that the Notch pathway, a developmental signaling pathway, can be reactivated and involved in the carcinogenesis of a number of cancers, including triple negative breast cancer, prostate cancer, pancreatic cancer and multiple myeloma. Recent efforts to target the Notch pathway have been limited by significant toxicity, such as observed gastrointestinal toxicity with gamma secretase inhibitors. Utilizing CytomX’s Probody therapeutics platform against Jagged and other novel targets within the Notch pathway represents an important opportunity to widen the therapeutic index and develop meaningful new cancer therapies.

Early Discovery
CytomX’s early discovery efforts are focused on additional targets in cancer and inflammation, that, without the Probody approach, would remain intractable due to widespread expression in normal tissues.